A hypothetical scheme targeting autophagy for glioblastoma sensitisation during radio-chemotherapy with TMZ Figure 1 from Michael I Achilleas G and.

Slides:



Advertisements
Similar presentations
THE GENETIC OF CANCER Increased mitosisTumor formation Tumor suppression gene Hyperactive growth TranslocationPoint mutationAmplification Normal growth.
Advertisements

Advanced Cancer Topics Journal Review 4/16/2009 AD.
Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.
Progress in Cancer Therapy Following Developments in Biopharma
YOUR CANCER TREATMENT: WHAT TO EXPECT FROM THE LATEST ADVANCEMENTS MIRIAM J. ATKINS, M.D.
Signal transduction. General scheme There are two general types of receptors: cell-surface and intracellular receptors.
Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor  Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.
Ramucirumab Protein chemical formula : C6374H9864N1692O1996S46
Schema for a human microbiome study
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.
Chemotherapy and Cancer Stem Cells
Targeting the PARP DNA repair pathway enhanced cytotoxicity induced by chemotherapy. Targeting the PARP DNA repair pathway enhanced cytotoxicity induced.
Immunotherapy of hepatocellular carcinoma
Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials  Pippa Newell, Augusto Villanueva, Josep M. Llovet 
Inhibitor of MAP kinase activation blocks colon cancer growth
Advances in Specific Immunotherapy for Prostate Cancer
Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients.
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Nat. Rev. Clin. Oncol. doi: /nrclinonc
The PI3K/Akt signalling and its activation in cancer
Nat. Rev. Clin. Oncol. doi: /nrclinonc
The hallmarks of adenovirus infection
The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.
Schematic diagram of antibody drug conjugate
Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma  Darshil J. Shah, MD, MPH, Roxana S. Dronca,
Figure 2 Co-stimulatory receptors as immunomodulatory targets
Figure 4 Combination immunotherapeutic approaches with imatinib
Figure 6 Combination therapy for HCC
Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.
The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
(A) An overview of the JAK/STAT signalling pathway.
Molecular approaches to HER2 targeted therapy
Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor  Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.
An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer Figure 1 from Eser et al. British Journal.
ADVANCED TARGETING SYSTEMS for specific elimination of cell types
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer
Model of the function of TBX2 in RMS.
Figure 2 from Sancho et al.
The cancer stem cell concept in cancer progression and metastasis
The putative genomic evolution of prostate cancer from normal epithelium to castrate-resistant, metastatic cancer Figure 2 from Mitchell and Neal British.
Figure 1 from B Zhu British Journal of Cancer (2015) 112, ; doi: /bjc
Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
Figure 2 Site of action of checkpoint inhibitors and agonists being
Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors  Su Jin Lee, MD, Jung-Il Lee,
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Figure 1 from M Holderfield
Molecular features of the colon during homeostasis and carcinogenesis
Figure 1 from T Schenk et al.
Fbxw7 ablation in LICs for CML sensitises the cells to imatinib by preventing quiescence. Figure 2 from S Takeishi British Journal of Cancer (2014) 111,
HDACs class I, II, IV mutations in human cancer
Translating Germline Cancer Risk into Precision Prevention
In melanoma tumours expressing the BRAFV600E oncogene RAF inhibitor treatment decreases ERK activation resulting in tumour regression and increased survival.
Figure 1 Mechanisms of action of immunotherapy modalities
Mitochondrial priming model
Nat. Rev. Cardiol. doi: /nrcardio
Ligands of Epidermal Growth Factor Receptor and the Insulin-Like Growth Factor Family as Serum Biomarkers for Response to Epidermal Growth Factor Receptor.
Spectrum of cellular processes regulated by AXL activity
Figure 1 from D’Incalci et al.
Involvement of actin cytoskeletal reorganisation in EMT
The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc
Target antigens for ADCs in solid tumours
Macrophage differentiation and their role in tumourigenesis
Model of EphA/ephrin-A expression in GBM.
by Jennifer Couzin-Frankel
Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)
Presentation transcript:

A hypothetical scheme targeting autophagy for glioblastoma sensitisation during radio-chemotherapy with TMZ Figure 1 from Michael I Achilleas G and Alexandra British Journal of Cancer Advance Online Publication 18 February 2016 doi:10.1038/bjc.2016.19 Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies. © 2016 Cancer Research UK.